CAPR Investors Have Opportunity to Lead Capricor Therapeutics, Inc. Securities Fraud Lawsuit with SBS Law

Schall, Brown & Schwartz LLP announced a class action securities fraud lawsuit against Capricor Therapeutics, Inc. (NASDAQ: CAPR) for allegedly making false and misleading statements regarding its Deramiocel drug candidate. The company allegedly changed its statistical analysis plan without FDA approval before resubmitting its Biologics License Application, creating significant risk of FDA rejection. The class period spans December 17, 2025 to July 26, 2026, with a September 28, 2026 deadline for investors to participate.